Beth A. Childs

Beth A. Childs

Auto-generated profile, based on publicly available information

Beth A. Childs

Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2025 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
JMJoseph F. Merola
Joseph F. Merola
AZArianna J. Zhang
Arianna J. Zhang
BCBeth A. Childs
Beth A. Childs
MLMingyue Li
Mingyue Li
JSJeffrey S Smith
Jeffrey S Smith
LPLourdes M. Pérez-Chada
Lourdes M. Pérez-Chada

9 June 2025 in Rheumatic Disease Clinics of North America
Verified
Journal Article
Closed access
BCBeth A. Childs
Beth A. Childs
JMJoseph F. Merola
Joseph F. Merola

7 April 2025 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
AZArianna J. Zhang
Arianna J. Zhang
NENnenna Ezeh
Nnenna Ezeh
BCBeth Childs
Beth Childs
SFSubrina Farah
Subrina Farah
JBJoy Buie
Joy Buie
JMJoseph F. Merola
Joseph F. Merola

3 March 2026 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
BCBeth A. Childs
Beth A. Childs
EEEslam A. Elghonaimy
Eslam A. Elghonaimy
SDSridevi Devaraj
Sridevi Devaraj
KKKiran A. Kumar
Kiran A. Kumar
JMJoseph F. Merola
Joseph F. Merola
TATodd A. Aguilera
Todd A. Aguilera
Background: Sézary syndrome (SS) and leukaemic mycosis fungoides (MF) are aggressive cutaneous T‐cell lymphomas (CTCLs) with poor prognosis and limited treatment options. Single‐cell RNA sequencing (scRNA‐seq) offers an opportunity to dissect malignant heterogeneity and immune dysregulation yet has been underutilized in leukaemic CTCL. Objectives: To define transcriptional heterogeneity within malignant T cells, identify immunomodulatory signals shaping the tumour microenvironment and uncover actionable vulnerabilities in SS and leukaemic MF. Methods: We analysed 144,321 peripheral blood mononuclear cells from 22 patients (SS or leukaemic MF) and 7 healthy controls using scRNA‐seq, with CITE‐seq and TCR‐seq in subsets. Public and prospectively collected datasets were integrated after rigorous per‐sample quality control, batch correction and malignancy assignment. Differential gene expression and cell–cell communication analyses were performed using complementary modelling approaches with correction for sparsity and multiple testing. Results: Three transcriptionally distinct malignant T‐cell (MTC) subtypes were identified: central memory‐like (MTC CM), effector/effector memory‐like (MTC E/EM) and regulatory‐like (MTC Reg), each with unique expression programmes and putative vulnerabilities. MTC CM, the dominant population, expressed central memory markers, Th2/Th22 skewing and a broader KIR repertoire ( KIR3DL2, KIR3DL1, KIR2DL3 ) than previously reported. MTC E/EM and MTC Reg were enriched for NR4A1 and ITGB1 , respectively. Cell–cell communication analysis revealed KIR–MHC‐I signalling and suggested that MTC‐derived TNF and IL‐10 may drive JAK/STAT pathway activity in non‐T cells, indicating an underrecognized dimension of tumour‐induced immune reprogramming. Conclusions: This is one of the most comprehensive single‐cell studies of leukaemic CTCL to date. We uncover new malignant T‐cell states, broaden the known repertoire of KIR expression, and propose mechanisms of immune evasion that may contribute to treatment resistance. These findings lay the groundwork for subtype‐specific and microenvironment‐informed therapeutic strategies in Sézary syndrome, with potential implications for guiding targeted therapy selection but require validation in larger, independent cohorts.

9 March 2026 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
VGVictoria Garfinkel
Victoria Garfinkel
BCBeth A Childs
Beth A Childs
BJBrielle E Johnson
Brielle E Johnson
KKKiran A Kumar
Kiran A Kumar
TATodd A Aguilera
Todd A Aguilera
HGHeather W Goff
Heather W Goff
Dear Editor, Cutaneous T-cell lymphomas (CTCLs) are rare non-Hodgkin lymphomas, affecting 8.8 per 1 000 000 people annually.1 Bexarotene is the only retinoid approved by the US Food and Drug Administration for mycosis fungoides (MF),2 the most common CTCL subtype, but its use is limited by high cost and adverse effects, particularly thyroid and lipid abnormalities.3 Acitretin, a less expensive second-generation retinoid used in psoriasis, is prescribed off-label in MF, yet supporting data remain limited to small retrospective case series.4 However, our clinical experience suggests dose-dependent efficacy with acitretin, supporting formal evaluation of its dose–response pattern in MF.

17 September 2024 in The American Journal of Dermatopathology
Verified
Journal Article
Closed access
BCBeth A. Childs
Beth A. Childs
JKJiwoong Kim
Jiwoong Kim
RPRavi R. Patel
Ravi R. Patel
TVTravis W. Vandergriff
Travis W. Vandergriff
HGHeather W. Goff
Heather W. Goff
RWRichard Wang
Richard Wang